印度購買止咳糖漿的新規定
New Indian rules for buying cough syrup
Updated at: June 17, 2026 at 07:30 AM
自2026年6月起，印度針對止咳糖漿的購買方式實施了重大變革。
Starting in June 2026, India has introduced significant changes to how cough syrups are purchased.
政府正式禁止所有糖漿類藥物的非處方（OTC）銷售，這些藥物此前是根據《1945年藥物規則》中的豁免條款銷售的。
The government has officially banned the over-the-counter (OTC) sale of all syrup-based medicines, which were previously accessible under exemptions in the Drugs Rules, 1945.
現在，每次購買都必須出示由註冊醫師開立的有效處方。
Now, a valid prescription from a registered doctor is mandatory for every purchase.
此項政策調整旨在抑制自行服藥並防止對含可待因產品的濫用。
This policy change aims to curb self-medication and prevent the abuse of codeine-based products.
這些更嚴格的法規是在發生一系列令人心碎的事件後制定的，當時含有二甘醇和乙二醇等致命物質的受汙染止咳糖漿，被發現與國內外的兒童死亡案例有關。
These stricter regulations follow a series of heartbreaking incidents where contaminated cough syrups—containing lethal substances like diethylene glycol and ethylene glycol—were linked to child fatalities both internationally and within India.
除了零售變更外，政府還徹底改革了製造標準。
In addition to retail changes, the government has overhauled manufacturing standards.
所有生產商現在必須遵守與世界衛生組織（WHO）標準接軌的修訂版「優良製造規範」（GMP）。
All producers must now follow revised 'Good Manufacturing Practices' (GMP) that align with World Health Organization standards.
此外，政府也嚴格執行對所有成品液體藥物進行有毒汙染物的強制檢測。
Furthermore, mandatory testing for toxic contaminants in all finished liquid medicines is now strictly enforced.
針對出口產品，印度公司必須提供由認可實驗室出具的分析證書，以確保符合全球安全預期。
For exports, Indian companies must provide a Certificate of Analysis from accredited laboratories, ensuring that global safety expectations are met.
這些綜合措施體現了印度致力於恢復其製藥產業信譽，並將公共衛生置於首位的決心。
These comprehensive measures represent India's commitment to restoring trust in its pharmaceutical sector and prioritizing public health above all else.
